**Wednesday, October 29, 2014**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration Open</td>
<td>2:00 PM – 8:30 PM</td>
</tr>
<tr>
<td>Exhibit Hall Open</td>
<td>7:30 PM – 9:00 PM</td>
</tr>
</tbody>
</table>

**ATA/AACE Advanced Endocrine Neck Ultrasound Course** 7:00 AM – 5:00 PM  
Chairs: Susan Mandel and Robert Levine

**E. Chester Ridgway Trainee Conference** 7:00 AM – 5:00 PM  
Chairs: Andrew Gianoukakis and Stephanie Fish

**Welcome/Opening Remarks** 5:30 PM – 5:45 PM  
Hossein Gharib, ATA President  
John C. Morris, III, Secretary/COO  
R. Michael Tuttle, Program Co-Chair  
Fredric Wondisford, Program Co-Chair

**Opening Session: Recent Developments and Future Challenges in Thyroidology** 5:45 PM – 7:30 PM  
*Chairs: R. Michael Tuttle and Fredric Wondisford*  
Basic: Peter Kopp  
Clinical: Douglas Ross  
Surgical: Herb Chen

**ATA Welcome Reception** 7:30 PM – 9:00 PM
84th Annual Meeting of the ATA  
Thursday, October 30, 2014

Registration Open 6:30 AM – 5:30 PM

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Early Riser Symposium: Medullary Thyroid Cancer</strong></td>
<td>6:45 AM – 8:00 AM</td>
<td>Chair: Jennifer Sipos</td>
</tr>
<tr>
<td>Prophylactic Thyroidectomy in MEN2: When and Why?</td>
<td></td>
<td>Steven Waguespack</td>
</tr>
<tr>
<td>Management of Persistent/Recurrent Disease in the Neck</td>
<td></td>
<td>Jeffrey Moley</td>
</tr>
<tr>
<td>Management of Persistent/Recurrent Disease in Distant Sites</td>
<td></td>
<td>Manisha Shah</td>
</tr>
<tr>
<td><strong>Plenary Lecture: Clinical, Ethical and Legal Implications of Incident Germ Line Findings Discovered as Part of Sequencing Studies</strong></td>
<td>8:10 AM – 8:55 AM</td>
<td>Introduction: R. Michael Tuttle</td>
</tr>
<tr>
<td><strong>Highlighted Oral Abstract Session</strong> (4 total)</td>
<td>9:00 AM – 10:00 AM</td>
<td>Speaker: Mark Robson</td>
</tr>
<tr>
<td><strong>Highlighted Oral Abstract 1, Autoimmunity, Clinical</strong></td>
<td></td>
<td>Peter Laurberg, D.C. Berman, I.B. Pedersen, S. Andersen, A. Carlé</td>
</tr>
<tr>
<td>DOUBLE VISION IS THE MOST COMMON INDICATION FOR THERAPY IN MODERATE TO SEVERE GRAVES' ORBITOPATHY BUT IT CORRELATES NEGATIVELY WITH INFLAMMATORY SIGNS AND PROPTOSIS. A SINGLE CENTER PROSPECTIVE COHORT STUDY (N=215) WITH OBJECTIVE QUANTITATION OF DIPLOPIA.</td>
<td></td>
<td>Chun-Rong Chen, P. Hubbard, S.M. McLachlan, R. Murali, B. Rapoport</td>
</tr>
<tr>
<td><strong>Highlighted Oral Abstract 2, Autoimmunity, Translational</strong></td>
<td></td>
<td>Sandra M. McLachlan, H. Aliesky, B. Banuelos, B. Rapoport</td>
</tr>
<tr>
<td>CRYSTAL STRUCTURE OF A TSH RECEPTOR MONOCLONAL ANTIBODY PROVIDES EVIDENCE THAT A TRIMER OF THE SHED RECEPTOR A-SUBUNIT IS THE CRITICAL IMMUNOGEN IN GRAVES' DISEASE</td>
<td></td>
<td>Risheng Ma, R. Latif, T.F. Davies</td>
</tr>
<tr>
<td><strong>Highlighted Oral Abstract 3, Autoimmunity, Translational</strong></td>
<td></td>
<td>DEVELOPMENT OF A UNIQUE MOUSE MODEL FOR GRAVES' DISEASE THAT SPONTANEOUSLY DEVELOPS PATHOGENIC TSH RECEPTOR ANTIBODIES</td>
</tr>
<tr>
<td><strong>Highlighted Oral Abstract 4, Thyroid &amp; Development, Basic</strong></td>
<td></td>
<td>Risheng Ma, R. Latif, T.F. Davies</td>
</tr>
<tr>
<td>DIFFERENTIATION OF HUMAN EMBRYONIC STEM (HES) CELLS INTO THYROID CELLS</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Meet the Professor Workshops (5 total)</strong></td>
<td>11:00 AM – 12:00 PM</td>
<td>Clinical</td>
</tr>
<tr>
<td>Thyroid Disease and Pregnancy</td>
<td>Robin Peeters</td>
<td></td>
</tr>
<tr>
<td>Management of Persistent/Recurrent Differentiated Thyroid Cancer: When to Treat, When to Watch?</td>
<td>Mona Sabra and Gary Clayman</td>
<td></td>
</tr>
<tr>
<td>TSH Suppression in Thyroid Cancer: Optimizing Risks vs. Benefits</td>
<td>Irwin Klein and Anne Cappola</td>
<td></td>
</tr>
<tr>
<td>Fukushima Daiichi Accident and Thyroid Cancer</td>
<td>Shigenobu Nagataki</td>
<td></td>
</tr>
<tr>
<td><strong>Lunch and Poster Review on Your Own</strong></td>
<td>12:00 PM – 12:55 PM</td>
<td></td>
</tr>
<tr>
<td><strong>ATA Committee Meetings Luncheon</strong> (for 2014 ATA Committee members)</td>
<td>12:00 PM – 12:55 PM</td>
<td></td>
</tr>
<tr>
<td><strong>ATA Expo Theater with Bayer Healthcare/Onyx Pharmaceuticals</strong></td>
<td>12:00 PM – 12:55 PM</td>
<td>NEXAVAR® (sorafenib) in Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Treatment: The Phase 3 DECISION Trial</td>
</tr>
<tr>
<td>(Open to all attendees; space limited – first come, first served)</td>
<td>Speaker: Ezra Cohen, MD</td>
<td></td>
</tr>
<tr>
<td><strong>Sidney H. Ingbar Award Lecture: Role of Thyroid Hormones in Skeletal Development and Bone Maintenance</strong></td>
<td>1:00 PM – 1:45 PM</td>
<td>Introduction: Sheue-yann Cheng</td>
</tr>
<tr>
<td>Speaker: Graham Williams</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Early Riser Symposium: Radioactive Iodine Remnant Ablation: Selecting the Proper Patients, Preparation Method and Administered Activity 6:45 AM – 8:00 AM

**Chair:** Laura Boucai

- Risk Stratification in Differentiated Thyroid Cancer  Fabian Pitoia
- Guidelines for Patient Selection for Radioactive Iodine Ablation  Leonard Wartofsky
- ESTIMBL and Hi-Lo: What Did We Learn, What Is Next? Ujjal Mallick

### Van Meter Lecture 8:10 AM – 8:55 AM

**Introduction:** To be announced onsite

**Speaker:** To be announced onsite

### Simultaneous Symposia 9:00 AM – 10:15 AM

**Clinical: ICCIDD Iodine Deficiency Symposium**

*(Dedicated to the Memory of Gerard “Gerry” Burrow)*

**Chairs:** Elizabeth Pearce and Angela Leung

- Iodine in Veterinary Populations  Charlene Edinboro
- David Marine and the Elimination of Endemic Goiter in the United States  J. Woody Sistrunk

**Basic: Thyroid Hormone Regulation of Growth and Development**

**Chair:** Anthony Hollenberg

- Thyroid Hormone and the Auditory System  Douglas Forrest
- The Role of Thyroid Hormone on Cerebral Cortex  Beatriz Morte Molina
- Roles of Thyroid Hormone Receptors in the Regulation of Thyroid Growth  Sheue-yann Cheng

### Simultaneous Symposia 11:15 AM – 12:30 PM

**Arthur Bauman Clinical Symposium:**

**Behind the Scenes - Difficult Decisions, Controversies and Logic in Developing ATA Guidelines**

**Chair:** Glenn Braunstein

- Thyroid Nodules and Differentiated Thyroid Cancer Guidelines  Bryan Haugen
- Medullary Thyroid Cancer Guidelines  Samuel Wells
- Hypothyroidism Guidelines: To T3 or Not to T3 and Other Questions About the Treatment of Hypothyroidism  Jacqueline Jonklaas

**Basic: The Journey of Thyroid Hormone into the Cell Nucleus**

**Chair:** Sheue-yann Cheng

- Cell Membrane Transporter  Heike Heuer
- Cellular Deiodinase Regulation  Elizabeth McAninch
- Role of Transthyretin in Placental Thyroid Hormone Transport  Kerry Richard

### Lunch and Poster Review on Your Own 12:30 PM – 1:25 PM

### ATA Women in Thyroidology Networking Meeting 12:30 PM – 1:25 PM

### ATA Expo Theater with Veracyte, Inc 12:30 PM – 1:25 PM

**The Scientific Story Behind Afirma Thyroid FNA Analysis**

*Open to all attendees; space limited – first come, first served*

**Speakers:** Giulia C. Kennedy and Richard T. Kloos

### Lewis E. Braverman Award Lecture: A Tale of Two Iodines: And the Braverman/Wartofsky Intersection 1:30 PM – 2:15 PM

**Introduction:** Elizabeth Pearce

**Speaker:** Leonard Wartofsky

### Meet the Professor Workshops (5 total) 2:20 PM – 3:20 PM

**Clinical**

- Serum Thyroglobulin in the Management of Differentiated Thyroid Cancer: An Update in 2014  Carole Spencer and Robert Smallridge
- Evaluation of Thyroid Nodules: What is the Role of Molecular Markers?  Julie Ann Sosa and Anna Sawka
- Evaluation and Management of Thyroid Nodules and Thyroid Cancer in the Pediatric Population  Stephen Huang

**Translational/Basic**

- ATA Basic Research Guidelines: How to Manipulate Thyroid Status in Animal Models  Tania Ortiga-Carvalho
- Role of TRs in Cell Differentiation and Senescence  Ana Aranda

### Clark T. Sawin Historical Vignette: Theodor Kocher (1841-1917) – A Lasting Legacy 3:25 PM – 3:50 PM

**Introduction:** Jeffrey Garber

**Speaker:** Peter Kopp

### Poster Review and Break 3:50 PM – 4:20 PM
### Oral Abstract Sessions 5:10 PM – 6:40 PM

<table>
<thead>
<tr>
<th>Oral Abstract 115, Thyroid Cancer, Basic</th>
<th>Oral Abstract 116, Thyroid Cancer, Basic</th>
</tr>
</thead>
<tbody>
<tr>
<td>MICRORNA-339-5P MODULATES NA+/I SYMPORTER-MEDIATED RADIOIODIDE UPTAKE</td>
<td>TARGETED DELIVERY OF A NOVEL HISTONE DEACETYLASE INHIBITOR, AB3, USING UNIMOLECULAR MICELLES TO IMPROVE ANTITUMOR EFFECT IN MEDULLARY THYROID CANCER</td>
</tr>
<tr>
<td>Aparna Lakshmanan, A. Wojcicka, M. Kotlarek, K. Jadzewski, S.M. Jhiang</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral Abstract 117, Autoimmunity, Basic</th>
<th>Oral Abstract 118, Thyroid Hormone Action, Basic</th>
</tr>
</thead>
<tbody>
<tr>
<td>STANDARDIZATION OF A FDA-CLEARED BIOASSAY CONVERTS THYROID-STIMULATING ANTIBODY LEVELS INTO INTERNATIONAL UNITS ENABLING COMPARISON AMONG LABORATORIES</td>
<td>THYROID HORMONE INTERACTS WITH ALPH2C ADRENERGIC RECEPTOR SIGNALING TO REGULATE THE EPIPHYSIAL GROWTH PLATE MORPHOLOGY AND BONE GROWTH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral Abstract 119, Disorders of Thyroid Function, Basic</th>
<th>Oral Abstract 120, Thyroid Hormone Metabolism &amp; Regulation, Basic</th>
</tr>
</thead>
<tbody>
<tr>
<td>THYROYCID CELL FATE</td>
<td>PHARMACOLOGICAL ACTIVATION OF THYROID HORMONE RECEPTORS ELICITS A FUNCTIONAL CONVERSION OF WHITE TO BROWN FAT</td>
</tr>
</tbody>
</table>

### Oral Abstract 120, Thyroid Cancer, Clinical

**Tumor Suppressor Mir-30a-5p Inhibits Lox Expression and Cancer Progression in Thyroid Cancer**


** Highly Accurate Diagnosis of Cancer in Thyroid Nodules with Follicular Neoplasm/Suspicious for a Follicular Neoplasm Cytology by Thyroseq V2 Next Generation Sequencing Assay**


**Mutational Analysis of Kinome in Differentiated Thyroid Cancer**


**Development of a Clinical Targeted Next-Generation Sequencing Test for Indeterminate Thyroid Nodules**


**Identification of Iodine Metabolism-Associated Large Non-Coding RNA (LincRNA) Differentially Expressed in Brafv600e-Positive Papillary Thyroid Cancer Versus Normal Thyroid Tissue**

**M. Duquette, A. Fischer, E. Puxeddu, J. Lawler, P. Pandolfi, Carmelo Nucera**
**84th Annual Meeting of the ATA**  
Saturday, November 1, 2014

**Registration Open** 6:30 AM – 5:30 PM

**Early Riser Symposium: Management of Advanced Radioactive Iodine Refractory Thyroid Cancer**  
6:45 AM – 8:00 AM  
*Chair: Maria E. Cabanillas*

What is the Definition of Radioactive Iodine Refractory? Stephanie Lee  
Opportunities for the Use of Locoregional/Directed Therapies in Radioiodine-Refractory Thyroid Cancers Keith Bible  
Initiation of Systemic Therapy: Which Agents and When? Rossella Elisei

**Plenary Lecture: Excess Thyroid Hormone and Thyrotroph Cell Death**  
8:10 AM – 8:55 AM  
*Introduction: Yun-Bo Shi*  
*Speaker: Rolf Karlstrom*

**Short Call Oral Abstracts** (6 total) 9:00 AM – 10:30 AM

*Chairs: Elizabeth Pearce and Antonio Bianco*

**Short Call Oral 1, Thyroid Cancer, Translational**  
TERT PROMOTER AND BRAF MUTATIONS COOPERATIVELY PROMOTE PAPILLARY THYROID CANCER-RELATED MORTALITY  
*Mingzhao Xing, R. Liu, J. Bishop*

**Short Call Oral 2, Thyroid Cancer, Basic**  
NF2/MERLIN IS A NOVEL THYROID TUMOR SUPPRESSOR GENE WHOSE LOSS PROMOTES ONCOGENIC RAS-INDUCED THYROID CANCERS VIA YAP-DEPENDENT TRANSACTIVATION OF MUTANT RAS AND SENSITIZES THEM TO MEK INHIBITION  

**Short Call Oral 3, Thyroid Cancer, Translational**  
TARGETING OF ONCOGENIC HRAS IN MURINE AGGRESSIVE THYROID CANCERS WITH MEK AND FARNESYLTRANSFERASE INHIBITION  
*Brian R. Untch, J.A. Knauf, M.E. Garcia-Rendueles, R.A. Ghossein, A.L. Ho, J. Fagin*

**Short Call Oral 4, Autoimmunity, Translational**  
MUTATIONS IN NOX3 AS GENETIC CAUSE OF FAMILIAL AGRANULOCYTOSIS DURING THYROSTATIC TREATMENT OF GRAVES’ DISEASE  

**Short Call Oral 5, Thyroid Cancer, Translational**  
IDENTIFICATION OF NOVEL GENE FUSIONS BY TARGETED NEXT-GEN SEQUENCING IN THYROID FNA SAMPLES  
*Marina Nikiforova, S. Zhong, A. Wald, L. Kelly, Y. Nikiforov*

**Short Call Oral 6, Thyroid Hormone Action, Basic**  
A ROLE FOR THYROID HORMONE ACTIVATION IN THE TREATMENT OF X-LINKED ADRENOLEUKODYSTROPHY (X-ALD)  
*Mercedith D. Hartley, T. Banerji, T.S. Scanlan*

**Exhibit Hall Open** 9:30 AM – 1:30 PM

**Poster Review Session and Break in the Exhibit Hall** 10:30 AM – 11:30 AM

**Meet the Professor Workshops** (5 total) 11:30 AM – 12:30 PM

<table>
<thead>
<tr>
<th>Clinical</th>
<th>Basic/Translational</th>
</tr>
</thead>
</table>
| • Radioactive Iodine Therapy in Benign Goiter Laszlo Hegedus  
Correlating Outcomes with the Histological Description of Follicular Cell Derived Thyroid Cancers: What Is The Clinical Relevance? Ronald Ghossein and Victor Bernet  
Should BRAF Status Influence Initial Management Decisions in Differentiated Thyroid Cancer? Sally Carty and Kepal Patel | • What is New for Thyroid Hormone Transporters Theo Visser  
• ATA Basic Science Handbook Antonio Bianco |

**Lunch and Poster Review on Your Own** 12:30 PM – 1:25 PM

**ATA Expo Theater with MedImmune, Specialty Care Division of AstraZeneca** 12:30 PM – 1:25 PM

Clinical Considerations in Advanced Medullary Thyroid Cancer (MTC) Patient Management  
*(Only U.S. health care professionals are permitted to attend this program; space limited – first come, first served; lunch served)*  
*Speaker: Kate Newbold*

**Exhibit Hall Closes** 1:30 PM
### Clinical: Evolution of Imaging Modalities in Thyroid Cancer

**Chairs:** Ann Morsing and Ron Koenig

- Update on Sonography in Thyroid Cancer Surveillance and Novel Therapeutic Strategies for Nodal Metastases
  - Robert Lee
- FDG and Beyond: Evolution of Positron-Emission Tomography Tracers in Advanced Thyroid Cancers
  - Trond Velde Bogsrud
- Personalized Approaches in Thyroid Cancer Imaging - The Future
  - Ann Morsing

### Basic: Thyroid Hormone Receptors: Insights from Disease Models

**Chair:** Graham Williams

- Prereceptor Defects in Humans
  - Alexandra Dumitrescu
- TRHA Human Mutations
  - Carla Moran
- TRHB Human Mutations
  - Samuel Refetoff

**FREE EVENING**
Symposium: Contemporary Evaluation and Management of Thyroid Nodules
8:00 AM – 9:15 AM
Chair: Melanie Goldfarb

Using Ultrasound to Risk Stratify Thyroid Nodules and Guide Selection for FNA  Andrew Gianoukakis
Rationale Follow-up of Cytologically Benign Thyroid Nodules  Ralf Paschke
Minimally Invasive Therapy for Benign and Malignant Nodules  Enrico Papini

Thyroid Cancer Tumor Board  9:30 AM – 11:00 AM
Moderator: Steven I. Sherman

Endocrinology: Douglas Ball
Surgery: Ralph Tufano
Nuclear Medicine: Daniel A. Pryma
Radiation Oncology: James Brierley
Oncology: Marcia Brose
Pathology: Yuri Nikiforov

84th Annual Meeting Ends 11:00 AM